Summit Therapeutics

Summit Therapeutics EBITDA per Employee

The EBITDA per Employee of Summit Therapeutics (SMMT) as of Nov 22, 2026 is -796,192.45 USD. In the previous year, EBITDA per Employee was -334,849.06 USD — a change of 137.78% (lower).

EBITDA per Employee

-796,192.45USD

YoY

137.78%

Last updated:

EBITDA per Employee of Summit Therapeutics is 2024 -796,192.45 USD. EBITDA per Employee of Summit Therapeutics was 2023 -334,849.06 USD. It decreases by 137.78% lower compared to the previous year.

The Summit Therapeutics EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2017
-104,792.45 USD
Jan 1, 2018
46,754.72 USD
Jan 1, 2019
-99,886.79 USD
Jan 1, 2020
-192,566.04 USD
Jan 1, 2021
-321,396.23 USD
Jan 1, 2022
-236,641.51 USD
Jan 1, 2023
-334,849.06 USD
Jan 1, 2024
-796,192.45 USD
The Summit Therapeutics EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-796,192.45USD+137.78%
-334,849.06USD+41.50%
-236,641.51USD-26.37%
-321,396.23USD+66.90%
-192,566.04USD+92.78%
-99,886.79USD-313.64%
46,754.72USD-144.62%
-104,792.45USD+14.47%
-91,547.17USD+16.63%
-78,490.57USD+62.88%
-48,188.68USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Summit Therapeutics Stock analysis

What does Summit Therapeutics do? Summit Therapeutics Inc. is a global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines for the treatment of life-threatening and rare diseases. The company is headquartered in Massachusetts, USA and also has offices in Oxford, UK. Summit Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Summit Therapeutics stock

EBITDA per Employee of Summit Therapeutics is -796,192.45 USD in 2024.

EBITDA per Employee of Summit Therapeutics changed from -334,849.06 USD to -796,192.45 USD, representing a 137.78% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Summit Therapeutics since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Summit Therapeutics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Summit Therapeutics

All Key Metrics — Summit Therapeutics